Grant Shoebridge has over 15 years’ experience in pharmaceutical and biotechnology-related intellectual property.

For the past 5 years Grant has led IPTA’s political engagement (lobbying) strategy, particularly in relation to proposed changes to Australian patent legislation and innovation policy.

Grant is a recognised authority on gene-related patentable subject matter. He made submissions to a Senate Inquiry into the patentability of genes and biological material and was involved in IPTA’s intervention application to the High Court appeal in D’Arcy v Myriad Genetics Inc.

Grant also successfully acted for the Applicant in Arrowhead Research Corporation [2016] APO 70 – which set an important precedent in relation to the patentability of gene-based pharmaceutical inventions in Australia.

For three years, Grant was course coordinator for “Interpretation and Validity of Patent Specifications” which is part of the University of Technology, Sydney postgraduate law program, and the Masters in Intellectual Property, which provides a pathway to registration for Australian patent attorneys.

Grant joined the IPTA Council in 2016 and is currently Convenor of the Finance & Secretariat Committee and Co-Convenor of the Public Relations Committee.